Nucleome Therapeutics
Cracking the code of the non-coding genome
Most of the human genome doesn’t code for proteins – but it holds the instructions that control how our genes behave and the secrets to many diseases.
Nucleome combines cutting-edge 3D genome sequencing and AI to decode this regulatory genome, revealing hidden drivers of autoimmune and inflammatory disease. The company’s platform enables the discovery of genetically validated drug targets and supports more precise treatments based on how each patient’s DNA truly works.
Sector
Life Sciences
Stage
- Series A